Abstract | BACKGROUND: OBJECTIVES: The goals of this review were to summarize the pharmacology, pharmacokinetics, efficacy, and tolerability of pregabalin; review its approved uses in the management of neuropathic pain and refractory partial-onset seizures; and investigate its potential use in patients with GAD or SAD. METHODS: Relevant English-language literature was identified through a search of MEDLINE (1993-June 2006) and International Pharmaceutical Abstracts (2000-June 2006). The search terms included pregabalin, Lyrica, S-(+)-3 isobutyl-gaba, PN, DPN, diabetic peripheral neuropathy, PHN, postherpetic neuralgia, partial seizures, epilepsy, generalized anxiety disorder, and CI-1008. RESULTS: In 4 clinical trials in a total of 1068 patients with diabetic peripheral neuropathy, the patients receiving pregabalin 300 to 600 mg/d had significantly greater improvement in mean pain scores than placebo recipients (P < or = 0.01). Patients with postherpetic neuralgia receiving pregabalin 450 to 600 mg/d had significantly greater improvement in relief of pain and pain-related sleep interference than placebo recipients (P < or = 0.002). Patients with refractory partial-onset seizures who received pregabalin 150 to 600 mg/d (divided into 2 or 3 doses) concomitantly with antiepileptic drugs had significantly fewer seizures than placebo recipients (P < or = 0.001). In the 3 studies that evaluated the efficacy of pregabalin in patients with GAD or SAD, the patients receiving pregabalin 200 to 600 mg/d (divided into 2 or 3 daily doses) had a significantly greater reduction in mean pain scores on the Hamilton Anxiety Scale than placebo recipients (P < or = 0.01). Across all the reviewed clinical trials, the most commonly reported adverse effects (AEs) were those affecting the central nervous system, including somnolence (< or =50%), dizziness (< or =49%), and headache (< or =29%). AEs resulted in withdrawal from the study in < or =32% of patients. CONCLUSIONS:
|
Authors | Daniel M Tassone, Eric Boyce, Jennifer Guyer, Donald Nuzum |
Journal | Clinical therapeutics
(Clin Ther)
Vol. 29
Issue 1
Pg. 26-48
(Jan 2007)
ISSN: 0149-2918 [Print] United States |
PMID | 17379045
(Publication Type: Journal Article, Review)
|
Chemical References |
- Analgesics
- Anticonvulsants
- Pregabalin
- gamma-Aminobutyric Acid
|
Topics |
- Analgesics
(adverse effects, pharmacokinetics, pharmacology, therapeutic use)
- Anticonvulsants
(administration & dosage, adverse effects, pharmacokinetics, pharmacology, therapeutic use)
- Anxiety Disorders
(drug therapy)
- Clinical Trials as Topic
- Drug Interactions
- Epilepsies, Partial
(drug therapy)
- Humans
- Neuralgia
(drug therapy)
- Pregabalin
- gamma-Aminobutyric Acid
(adverse effects, analogs & derivatives, pharmacokinetics, pharmacology, therapeutic use)
|